Connect with us

Technology

Dye & Durham Reports Second Quarter Fiscal 2024 Financial Results

Published

on

Revenue up 17% to $110 million, taking into consideration the TM Group divestiture Annual Contracted Revenue of $203 million1, or 49% of total revenue as of December 31, 2023ARR was $112 million, or 27% of total revenue1,2 nearly doubling from the prior year

TORONTO, Feb. 13, 2024 /CNW/ – Dye & Durham Limited (“Dye & Durham” or the “Company”) (TSX: DND), one of the world’s largest providers of cloud-based legal practice management software, today announced its financial results for the three and six months ended December 31, 2023.

“We continued to build momentum this quarter, with double-digit revenue growth supported by our strong and growing base of Annual Contracted Revenue,” said Dye & Durham CEO, Matthew Proud. “We have made significant progress on our business performance plan and further enhanced our capital structure. As a result of our exciting new product launches, the success of our refreshed go-to-market strategy and our disciplined approach to managing cost, we are strongly positioned to grow organic revenue while continuing to reduce our leverage ratio to less than four times total net debt to Adjusted EBITDA.”

Contracted Revenue

The Company has two sources of contracted revenue:

Annual Recurring Revenue (ARR) which includes revenues from subscriptions and revenue from minimum spend contracts. ARR was $112 million of total revenue1,2 which was 27% of total revenue as of December 31, 2023. This is nearly doubling the 16% at the same point in the prior year.Other Contracted Revenue includes revenue from contracted overages and other service agreements. As of December 31, 2023, this amounted to $93 million.

In total, the Company’s Annual Contracted Revenue was $203 million1, or 49% of total revenue as of December 31, 2023.

Second Quarter Fiscal 2024 Highlights 

Revenue of $110.2 million, up 17% from the same period in the prior year taking into consideration the divestiture of TM Group (“TMG”) on August 3, 2023. The comparative period revenue in fiscal 2023 included an additional $12.5 million of revenue from TMG. Revenue grew 3%, including the impact of TMG in the comparative period.Net loss for the current quarter was $34.8 million, remaining relatively stable compared to the equivalent period in the prior year.Adjusted EBITDA3 of $60.0 million, an increase of $2.4 million, or 4%, from the same period in the prior year, despite the loss of contributed Adjusted EBITDA from the TM Group in the prior year.

Quarterly Dividend

On February 13, 2024, the Board of Directors declared a quarterly dividend of $0.01875 per share to shareholders of record on February 21, 2024, payable on or about February 28, 2024.

Conference Call Notification 

The Company will hold a conference call to discuss its business later today, Tuesday, February 13, 2024, at 8:00 a.m. ET hosted by senior management. A question-and-answer session will follow the corporate update.

DATE: Tuesday, February 13, 2024
TIME: 8:00 a.m. ET
RAPIDCONNECT: To instantly join the conference call by phone, please use the following URL to easily register and be connected into the conference call automatically: https://emportal.ink/3tUWLSF   

TRADITIONAL DIAL-IN NUMBER: (416) 764-8659 or (888) 664-6392
REFERENCE NUMBER: 57043673
TAPED REPLAY: (416) 764-8677 or (888) 390-0541
REPLAY CODE: 043673#

This call is being webcast and can be accessed by going to: https://app.webinar.net/J9qlmkZWoXP

As of December 31, 2023 on a run rate basis.Excluding TMG revenues.Represents a non-IFRS measure. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. For the relevant definition, see the “Non-IFRS Financial Measures” section of this press release. Management believes non-IFRS measures, including EBITDA and Adjusted EBITDA, provide supplementary information to IFRS measures used in assessing the performance of the business by providing further understanding of the Company’s results of operations from management’s perspective. Please see “Cautionary Note Regarding Non-IFRS Measures”, and “Select Information and Reconciliation of Non-IFRS Measures in the Company’s most recent Management’s Discussion and Analysis, which is available on the Company’s profile on SEDAR+ at www.sedarplus.ca, for further details on certain non-IFRS measures, including the relevant reconciliations of Adjusted EBITDA to its most directly comparable IFRS measure, which information is incorporated by reference herein.

About Dye & Durham

Dye & Durham Limited provides premier practice management solutions empowering legal professionals every day, delivers vital data insights to support critical corporate transactions and enables the essential payments infrastructure trusted by government and financial institutions. The company has operations in Canada, the United Kingdom, Ireland, Australia and South Africa.

Additional information can be found at www.dyedurham.com.

Non-IFRS Measures

This press release makes reference to certain non-IFRS measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies.

Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company’s results of operations from management’s perspective and to discuss Dye & Durham’s financial outlook. The Company’s definitions of non-IFRS measures may not be the same as the definitions for such measures used by other companies in their reporting. Non-IFRS measures have limitations as analytical tools. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of Dye & Durham’s financial information reported under IFRS. The Company uses non-IFRS measures, including “EBITDA”, and “Adjusted EBITDA”, (each as defined below), to provide investors with supplemental measures of its operating performance and to eliminate items that have less bearing on operating performance or operating conditions and thus highlight trends in its core business that may not otherwise be apparent when relying solely on IFRS financial measures. The Company’s management also uses non-IFRS financial measures in order to facilitate operating performance comparisons from period to period. The Company believes that securities analysts, investors, and other interested parties frequently use non-IFRS financial measures in the evaluation of issues.

Please see “Cautionary Note Regarding Non-IFRS Measures” and “Select Information and Reconciliation of Non-IFRS Measures” in the Company’s most recent Management’s Discussion and Analysis, which is available on the Company’s profile on SEDAR+ at www.sedarplus.ca, for further details on certain non-IFRS measures, including relevant reconciliations of each non-IFRS measure to its most directly comparable IFRS measure, which information is incorporated by reference herein.

EBITDA

EBITDA means net income (loss) before amortization and depreciation expenses, finance and interest costs including change in fair value of Company’s convertible debentures, loss on settlement of loans and borrowings, realized loss on derivatives, gains or losses from re-financing transactions and provision for income taxes. 

Adjusted EBITDA

Adjusted EBITDA adjusts EBITDA for stock-based compensation expense, loss on disposal of assets held for sale, specific transaction-related expenses related to acquisition, listing and reorganization related expenses, integration and operational restructuring costs. Operational restructuring costs are incurred as a direct or indirect result of acquisition activities. Operational restructuring costs include the full period impact of cost synergies related to the reduction of employees for acquisitions.

Forward-looking Statements

This press release may contain forward-looking information and forward-looking statements within the meaning of applicable securities laws, which reflects the Company’s current expectations regarding future events, including with respect to the Company’s financial outlook and business strategy, including its debt reduction strategy and business performance plan. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management’s current beliefs, expectations, estimates and projections regarding future events and operating performance.

Specifically, statements regarding Dye & Durham’s expectations of future results, performance, prospects, the markets in which we operate, or about any future intention with regard to its business, acquisition strategies, debt reduction strategy and business performance plan are forward-looking information. The foregoing demonstrates Dye & Durham’s objectives, which are not forecasts or estimates of its financial position, but are based on the implementation of its strategic goals, growth prospectus, and growth initiatives. The forward-looking information is based on management’s opinions, estimates and assumptions, including, but not limited to: (i) Dye & Durham’s results of operations will continue as expected, (ii) the Company will continue to effectively execute against its key strategic growth priorities, (iii) the Company will continue to retain and grow its existing customer base and market share, (iv) the Company will be able to take advantage of future prospects and opportunities, and realize on synergies, including with respect of acquisitions, (v) there will be no changes in legislative or regulatory matters that negatively impact the Company’s business, (vi) current tax laws will remain in effect and will not be materially changed, (vii) economic conditions will remain relatively stable throughout the period, (vii) the industries Dye & Durham operates in will continue to grow consistent with past experience, (ix) the seasonal trends in real estate transaction volume will continue as expected, * the Company’s expectations its debt reduction strategy will be met and (xi)  those assumptions described under the heading “Caution Regarding Forward-Looking Information” in the Company’s Management’s Discussion and Analysis for the second quarter ended December 31, 2023. While these opinions, estimates and assumptions are considered by Dye & Durham to be appropriate and reasonable in the circumstances as of the date of this press release, they are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by such forward-looking information.

The forward looking information is subject to significant risks including, without limitation: that the Company will be unable to effectively execute against its key strategic growth priorities, including in respect of acquisitions; the Company will be unable to continue to retain and grow its existing customer base and market share; risks related to the Company’s business and financial position; that Dye & Durham may not be able to accurately predict its rate of growth and profitability; risks related to economic and political uncertainty; income tax related risks; and those risk factors discussed in greater detail under the “Risk Factors” section of the Company’s most recent annual information form and under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, which are available under Dye & Durham’s profile on SEDAR+ at www.sedarplus.ca.  Many of these risks are beyond the Company’s control.

If any of these risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying the forward-looking information prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking information. Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information.

Although the Company bases these forward-looking statements on assumptions that it believes are reasonable when made, the Company cautions investors that forward-looking statements are not guarantees of future performance and that its actual results of operations, financial condition and liquidity and the development of the industry in which it operates may differ materially from those made in or suggested by the forward-looking statements contained in this press release. In addition, even if the Company’s results of operations, financial condition and liquidity and the development of the industry in which it operates are consistent with the forward-looking statements contained in this press release, those results of developments may not be indicative of results or developments in subsequent periods.

There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. No forward-looking statement is a guarantee of future results. Accordingly, you should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this press release represents Dye & Durham’s expectations as of the date specified herein, and are subject to change after such date. However, the Company disclaims any intention or obligation or undertaking to update or revise any forward-looking information or to publicly announce the results of any revisions to any of those statements, whether as a result of new information, future events or otherwise, except as required under applicable securities laws. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should only be viewed as historical data.

All of the forward-looking information contained in this press release is expressly qualified by the foregoing cautionary statements.

SOURCE Dye & Durham Limited

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Weibo Corporation to Report First Quarter 2026 Financial Results on May 28, 2026

Published

on

By

BEIJING, April 27, 2026 /PRNewswire/ — Weibo Corporation (NASDAQ: WB and HKEX: 9898), a leading social media for people to create, share and discover content, will announce its unaudited financial results for the first quarter 2026 before the U.S. market opens on Thursday, May 28, 2026. Following the announcement, Weibo’s management team will host a conference call from 7 AM – 8 AM Eastern Time on May 28, 2026 (or 7 PM – 8 PM Beijing Time on May 28, 2026) to present an overview of the Company’s financial performance and business operations.

Participants who wish to dial in to the teleconference must register through the below public participant link. Dial in and instruction will be in the confirmation email upon registering.

Participants Registration Link: https://register-conf.media-server.com/register/BIb549b1f6935046d98b52a0fe61be918e

Additionally, a live and archived webcast of this conference call will be available at http://ir.weibo.com.

About Weibo Corporation

Weibo is a leading social media for people to create, share and discover content online. Weibo combines the means of public self-expression in real time with a powerful platform for social interaction, content aggregation and content distribution. Any user can create and post a feed and attach multi-media and long-form content. User relationships on Weibo may be asymmetric; any user can follow any other user and add comments to a feed while reposting. This simple, asymmetric and distributed nature of Weibo allows an original feed to become a live viral conversation stream.

Weibo enables its advertising and marketing customers to promote their brands, products and services to users. Weibo offers a wide range of advertising and marketing solutions to companies of all sizes. The Company generates a substantial majority of its revenues from the sale of advertising and marketing services, including the sale of social display advertisement and promoted marketing offerings. Designed with a “mobile first” philosophy, Weibo displays content in a simple information feed format and offers native advertisement that conform to the information feed on our platform. To support the mobile format, we have developed and continuously refining our social interest graph recommendation engine, which enables our customers to perform people marketing and target audiences based on user demographics, social relationships, interests and behaviors, to achieve greater relevance, engagement and marketing effectiveness

Contact:
Investor Relations
Weibo Corporation
Phone: +86 10 5898-3336
Email: ir@staff.weibo.com 

View original content:https://www.prnewswire.com/news-releases/weibo-corporation-to-report-first-quarter-2026-financial-results-on-may-28-2026-302754018.html

SOURCE Weibo Corporation

Continue Reading

Technology

Perceptive eClinical Launches Technology-Enabled Clinical Supply Consultancy in Alliance with Trialzen

Published

on

By

Expert-led clinical supply strategy powered by advanced planning and analytics technologies.

NOTTINGHAM, England and LASNE, Belgium, April 27, 2026 /PRNewswire/ — Perceptive eClinical, a leading provider of interactive response technology (IRT) and eClinical solutions, and Trialzen, an expert-led Forecasting and Supply Technology company, today announced an alliance supporting Perceptive eClinical in the launch of its Clinical Intelligence Consultancy Service, Perceptive Clinical Intelligence. This transforms its long–standing clinical supply expertise into a fully integrated, expert–led service spanning the entire clinical trial lifecycle and enabled by Trialzen’s advanced clinical supply planning technologies.

Perceptive Clinical Intelligence combines Perceptive’s deep expertise in randomization and clinical supply optimization with data-driven, technology enabled mathematical optimization, simulation, and forecasting to support smarter planning across the trial lifecycle. This integrated offering helps sponsors design, stress test, and manage clinical supply strategies with greater confidence and operational control. By formalizing its in-house expertise and therapeutic experience, Perceptive unifies randomization, trial supply management technologies and clinical supply consulting to enable more informed, scalable, and lower risk supply decision making.

“Clinical trial supply decisions are too critical to rely on tools alone,” said Malcolm Morrissey, Head of Perceptive Clinical Intelligence. “While supply discussions often focus on stock levels and overage, the real risk is patient impact. Supply availability determines whether visits happen, treatment is delivered on time, and sites can operate with confidence. Effective supply management means looking beyond IP numbers to understand patient continuity and visit level risk across the entire trial.”

Industry benchmarks show that approximately 50% of Clinical Finished Goods (CFG) manufactured for clinical trials are never administered to patients, representing hundreds of millions of dollars in wasted drug supply each year1.

“Setting up Perceptive Clinical Intelligence reflects the next step in Perceptive’s evolution, combining deep clinical supply and randomization expertise with data–driven technology to enable smarter supply planning, and increased supply confidence, and continuity across the trial lifecycle,” said Shaun Hopgood, Chief Operating Officer at Perceptive eClinical.

Perceptive eClinical and Trialzen have each delivered proven results for sponsors, with real–world engagements generating savings exceeding $1 million and materially reducing supply overage.

A Technology Enabled, Expert-Led Approach

Delivered by Perceptive’s in–house specialists, the consultancy is built on 30 years of experience supporting biotech and large pharma across randomization and clinical supply management. It combines Perceptive’s proven supply–modelling expertise with Trialzen’s advanced calculation and simulation engine, fully integrated into Perceptive’s next–generation platform, Clinphone Pro.

Anchored in deep oncology expertise, where global scale, complex dosing, and multi–layered supply chains increase planning risk, the consultancy also draws on experience across Endocrinology and Metabolism, and Infectious Diseases, and supports emerging areas such as Precision and Nuclear Medicine, and Cell and Gene Therapies. 

Reflecting on this alliance and its objectives, Cedric Druck, CEO and Co–Founder of Trialzen, commented: “Trialzen was built by clinical supply experts who spent years watching planning decisions get made on spreadsheets and gut feel, then handed off to execution systems with no feedback loop. This collaboration with Perceptive closes that gap. By integrating our forecasting and simulation capabilities directly with their IRT platform, we enable sponsors to move from scenario planning to operational action in a single environment, with full transparency at every step.”

At the heart of this alliance is a shared belief that clinical supply planning and execution should live in one connected environment. “Together, Perceptive and Trialzen are working toward a unified way of operating, where strategic decisions and day–to–day execution come together, enabling greater visibility, smarter scenarios, and more confident supply decisions from manufacturing through to patient dosing”. said Tony Street, Senior Vice President Strategy at Trialzen.

Clients benefit from:

Faster study start-up and smoother amendments through early supply optimizationHigher quality supply decisions driven by expert oversight and data backed insightGreater confidence through strategic expert consultancy for complex trialsMid-study forecast adjustments and up-to-date quantitative support for key decisions

About Perceptive eClinical

Perceptive eClinical is a trusted leader in delivering advanced trial capabilities. With over 30 years of proven Interactive Response Technology (IRT) and supply management expertise, more than 500 regulatory approvals and support for three million patients worldwide, we deliver reliability, security and precision. This is reflected in our consistently high customer satisfaction score of 4.5 out of 5 over the past three years. Our future-proof IRT solution, Clinphone Pro, helps sponsors manage the speed, complexity and personalization of modern clinical trials. Built for flexibility and seamless integration, it supports smarter, more efficient studies across all phases and therapeutic areas. In 2025, Perceptive eClinical was recognized as a leader in Everest Group’s PEAK Matrix® Assessment for RTSM Solutions, affirming our commitment to innovation, global delivery excellence and measurable value for sponsors and CROs.

About Trialzen

Trialzen is a technology company built by industry experts specializing in clinical trial supply forecasting and planning. Its Forecast & Planning Solution (FPS) is a purpose-built SaaS platform that enables sponsors and CROs to model, simulate, and optimize clinical supply strategies across the full trial lifecycle. Built by clinical supply experts, Trialzen combines advanced mathematical modelling and analytics with a transparent, user-friendly interface, allowing teams to evaluate scenarios, anticipate risk, and make informed supply decisions with speed and confidence. 

Sources

McKinsey & Company, Clinical Supply Chains insights

Media Contact: Zara Broadfield, Marketing Director Perceptive eClinical, zara.broadfield@perceptive.com 

Logo – https://mma.prnewswire.com/media/2965426/Perceptive_eClinical.jpg
Logo – https://mma.prnewswire.com/media/2965427/5936695/Trialzen.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/perceptive-eclinical-launches-technologyenabled-clinical-supply-consultancy-in-alliance-with-trialzen-302754074.html

Continue Reading

Technology

Mouser Electronics New Product Insider: Over 9,000 New Parts Added in First Quarter of 2026

Published

on

By

SHANGHAI, April 27, 2026 /PRNewswire/ — As an authorized distributor, Mouser Electronics, Inc. is focused on the rapid introduction of new products and technologies, giving customers an edge and helping speed time to market. Over 1,200 semiconductor and electronic component manufacturer brands count on Mouser to help them introduce their products into the global marketplace. Mouser’s customers can expect 100% certified, genuine products that are fully traceable from each manufacturer.

Last quarter, Mouser launched more than 9,000 part numbers ready for shipment. Some of the products introduced by Mouser from January through March 2026 include:

STMicroelectronics STM32C5 Arm® Cortex®-M33 Microcontrollers
The STM32C5 microcontrollers (MCUs) from STMicroelectronics are specifically designed to boost the performance of billions of tiny smart devices across factories, homes, cities, and infrastructure while meeting stringent cost, size, and power constraints. Based on ST’s proprietary 40 nm manufacturing process, the STM32C5 MCUs can run tasks noticeably faster than many entry-level chips currently in use. This gives products more room to include features such as improved sensing, smoother control, and enhanced user experiences while keeping dynamic power consumption low. The MCUs also integrate security features that help safeguard products against tampering and cyber risks.EDATEC ED-CM0NANO Single-Board Computer
The ED-CM0NANO is a single-board computer (SBC) from EDATEC, based on the Raspberry Pi Compute Module Zero (CM0). The ED-CM0NANO features a quad-core Arm Cortex-A53 processor running at up to 1 GHz, a Broadcom VideoCore-IV graphics processor, and a wide range of connectivity options. Optional Wi-Fi® support with an external antenna enables wireless connectivity, while integrated real-time clock (RTC) and watchdog timer enhance system reliability. These features make the ED-CM0NANO ideal for industrial control systems and Internet of Things (IoT) applications.Sensata Technologies MGD Resonix™ Refrigerant Leak Sensor
The MGD Resonix™ sensor from Sensata delivers high accuracy and fast response times in a compact module that fits into the smallest heating, ventilation, air conditioning (HVAC), and refrigeration equipment. The MGD series offers superior resistance to overexposure and poisoning, as well as to high temperatures (working temperatures up to 105 °C) and humidity. These devices also have a service life of more than 15 years with no need for calibration, making them the ideal leak-detection component for A2L HVAC and refrigeration systems.u-blox ANN-MB3 Triple-Band GNSS Antenna
The ANN-MB3 from u-blox is a best-in-class L1/L2/L5 triple-band RTK real-time kinematic (RTK) solution ideal for the F20 high-precision GNSS. Optimized for seamless integration, the ANN-MB3 antenna delivers exceptional performance with a robust design. The antenna’s compact (62 × 80 × 25.5 mm) form factor and flexible installation options enable the adoption of high-precision positioning technologies across industrial, automotive, and robotics applications.

To see more of the New Product Insider highlights, go to https://info.mouser.com/new_products/.

For more Mouser news and our latest new product introductions, visit https://www.mouser.com/newsroom/.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/mouser-electronics-new-product-insider-over-9-000-new-parts-added-in-first-quarter-of-2026–302754079.html

SOURCE Mouser Electronics

Continue Reading

Trending